Methods. Adults ≥ 50 years of age seeking medical care for acute respiratory illness November through April 2008 April -09, 2010 April -11 & 2011 were eligible. Influenza cases and controls were identified by positive and negative RT-PCR, respectively.
We ascertained exposure to seasonal influenza split virion vaccine (Afluria, Fluarix, FluLaval, & Fluzone Standard Dose) or subunit vaccine (Agriflu & Fluvirin) ≥2 weeks prior to the visit. Fluzone High Dose recipients were excluded. Covariates included age, sex, race, smoking, oxygen use, insurance, medical conditions, immunosuppression, week of ARI visit, influenza season, & site of enrollment. Vaccine effectiveness (VE) for split vaccine versus no vaccine and subunit vaccine versus no vaccine were estimated as [(1-adjusted odds ratio) x 100] using logistic regression models with L1 penalty on all covariates except vaccine type (LASSO). The relative VE was calculated as the VE difference.
Results. We enrolled 840 participants of whom 539 had a known immunization status and complete clinical data. Compared to influenza negative patients, the 68 (12.6%) influenza positive patients were younger ( p < 0.001), more likely to have been enrolled in the hospital than in either the emergency department or the acute care clinic ( p = 0.001), and more likely to have received subunit than split-virion vaccine (<0.001). Patients who received split-virion vaccines (n = 204) were similar to those (n = 150) who received subunit vaccines except for the proportion who were influenza positive (5.4% vs.12%, p = 0.02). VE for the split influenza vaccine was 77.8% (58.5%, 90.3%) while that of the subunit vaccine was 44.3% (-11.8%, 70.9%) . Relative VE for split-viron compared to subunit vaccines was 33.5%, (95% CI: 6.9%, 86.7%).
Conclusion. 
